

PRESS RELEASE

Pascal Apostolides elected new President of SFEE

Athens, 23 March 2015 – Today, SFEE’s new Board of Directors held its first meeting and constituted itself as follows:

President was elected unanimously Mr Pascal Apostolides, General Manager at AbbVie Pharmaceuticals.

Alternate President was elected unanimously Mr Konstantinos Panagoulis, General Manager at Vian and Vice-President at Vianex.

Vice Presidents were elected Msrrs:

Konstantinos Evripidis (CEO, Genesis Pharma), responsible for issues related to Arrears / Bonds / Taxation

Stavros Theodorakis (Managing Director for Greece and Cyprus, Chiesi), responsible for issues related to EOF

Marios Kosmidis (General Manager, Win Medica), responsible for issues related to EOPYY / Reimbursement List / Clawback;

Konstantinos Panagoulis (General Manager, Vian, and Vice President, Vianex), responsible for issues related to Growth and Hospitals;

Olympios Papadimitriou (General Manager, Novo Nordisk Hellas), responsible for issues related to Pricing;

Spyros Filiotis (Vice-President and General Manager, Pharmaserve-Lilly), responsible for the Special Clinical Trials Committee.

Secretary-General was elected Mr. Konstantinos Kofinas, (President and Managing Director for Greece and Cyprus at Merck), responsible also for the Special Substantiation Secretariat.

Treasurer was elected Mr. Nikolaos Varelas, General Manager at Galenica.

Members of the Board are Msrrs:

Roberto Greco, President and General Manager Greece and Cluster Area Director Adriatics, GlaxoSmithKline Hellas – President of PhRMA Innovation Forum Greece

Dimitris Anagnostakis, President and Managing Director for Greece and Cyprus, Boehringer Ingelheim

Marcos Gerassopoulos, Chairman & Managing Director and General Manager of Sanofi Aventis Greece

Mario Katsikas (President and Managing Director, Proton Pharma) and Substitute Member responsible for issues related to Pricing

Nikolaos Kefalas, President and Managing Director, Janssen-Cilag Greece

Konstantinos Frouzis, Vice-President and General Manager, Novartis Hellas.

The President and the members of the Board of Directors undertake to steer SFEE through one of the most challenging times our country has experienced in decades.

The newly elected President, Mr. Apostolides, stressed that pharmaceutical companies can be a dual force for economic growth and for an active support to the welfare state and public health, adding that “By establishing relations of trust with the State, which will lead to realistic decisions, we can provide to the economy and society of our country the support they need for a better future”.

A key priority for SFEE is also to maintain and promote entrepreneurship among both domestic companies and multinationals operating in Greece. Finally, SFEE remains unwaveringly committed to ensuring the access of all patients to treatments, especially to innovative treatments, as a factor that promotes social solidarity and cohesion in our country.